Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Active not recruiting 4Recruiting 1Completed 1

Sponsor Class

INDUSTRY 113OTHER 60NETWORK 6NIH 3OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 4Recurrence 1Genetic Diseases, Inborn 1Breast Neoplasm Female 1

Interventions

Specimen Handling 68Magnetic Resonance Spectroscopy 53Cyclophosphamide 45Vincristine 38Radiotherapy 31Radiation 31Cisplatin 31Carboplatin 30Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Platinum 16Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NETWORK × Fulvestrant × 1 year × Clear all
NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Recruiting
484 enrolled
Breast

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Completed
180 enrolled 14 charts
Breast

Breast Neoplasms

NCT04650581 2026-04-13

FINER

Canadian Cancer Trials Group

Phase 3 Active not recruiting
250 enrolled 13 charts
Breast

Breast Neoplasms

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡